Pasar al contenido principal

IDENTIFICACION DE MECANISMOS QUE OPERAN EN LA EVOLUCION DE PROTEINAS USANDO DESCRIPTORES: IMPACTO EN APLICABILIDAD

RTI2018-096735-B-I00

•
Nombre agencia financiadora Agencia Estatal de Investigación
Acrónimo agencia financiadora AEI
Programa Programa Estatal de I+D+i Orientado a los Retos de la Sociedad
Convocatoria Proyectos I+D+i Retos de Investigación
Año convocatoria 2018
Plan Estatal 2017-2020 Plan Estatal de Investigación Científica y Técnica y de Innovación
Centro beneficiario AGENCIA ESTATAL CONSEJO SUPERIOR DE INVESTIGACIONES CIENTIFICAS (CSIC)

Resultados relacionados

Resultados totales (Incluyendo duplicados): 3
Encontrada(s) 1 página(s)

DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Non-canonical dimerization of the androgen receptor and other nuclear receptors: implications for human disease

  • Jiménez-Panizo, Alba
  • Pérez, Paloma
  • Rojas Mendoza, Ana M.
  • Fuentes-Prior, Pablo
  • Estébanez-Perpiñá, Eva
18 páginas, 5 figuras, 1 tabla, Nuclear receptors are transcription factors that play critical roles in development, homeostasis and metabolism in all multicellular organisms. An important family of nuclear receptors comprises those members that respond to steroid hormones, and which is subdivided in turn into estrogen receptor (ER) isoforms α and β (NR3A1 and A2, respectively), and a second subfamily of so-called oxosteroid receptors. The latter includes the androgen receptor (AR/NR3C4), the glucocorticoid receptor (GR/NR3C1), the mineralocorticoid receptor (MR/NR3C2) and the progesterone receptor (PR/NR3C3). Here we review recent advances in our understanding of the structure-and-function relationship of steroid nuclear receptors and discuss their implications for the etiology of human diseases. We focus in particular on the role played by AR dysregulation in both prostate cancer (PCa) and androgen insensitivity syndromes (AIS), but also discuss conditions linked to mutations of the GR gene as well as those in a non-steroidal receptor, the thyroid hormone receptor (TR). Finally, we explore how these recent results might be exploited for the development of novel and selective therapeutic strategies., E E P expresses her deepest gratitude to the generous and continuous private donations from Gemma E Carretero. E E P, P F P and P P acknowledge the RED Nacional de Receptores Nucleares (NurCaMeIn: SAF2017-71878-REDT and SAF2015-71878-REDT). E E P acknowledges the BFU-Retos2017-86906-R, P F P the SAF2014-57994-R, P P the SAF2017-88046-R and A R the RTI2018-096735-B-100 grants from the MINECO. E E P and P F P are thankful for the CaixaImpulse2017 (ARDIs) from La Caixa (Fundación Bancaria Caja de Ahorros y Pensiones de Barcelona, Obra Social La Caixa y Caixa Risc) and SGR2017 and LLAVOR2018 grants from the Generalitat de Catalunya. E E P acknowledges the F2I-FVAL and F2I-MiR grants from the EU FEDER and the Fundació Bosch i Gimpera (FBG)., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Mutation of SPINOPHILIN (PPP1R9B) found in human tumors promotes the tumorigenic and stemness properties of cells

  • Verdugo-Sivianes, Eva M.
  • Rojas Mendoza, Ana M.
  • Muñoz-Galván, Sandra
  • Otero-Albiol, Daniel
  • Carnero, Amancio
[Rationale] SPINOPHILIN (SPN, PPP1R9B) is an important tumor suppressor involved in the progression and malignancy of different tumors depending on its association with protein phosphatase 1 (PP1) and the ability of the PP1-SPN holoenzyme to dephosphorylate retinoblastoma (pRB)., [Methods] We performed a mutational analysis of SPN in human tumors, focusing on the region of interaction with PP1 and pRB. We explored the effect of the SPN-A566V mutation in an immortalized non-tumorigenic cell line of epithelial breast tissue, MCF10A, and in two different p53-mutated breast cancer cells lines, T47D and MDA-MB-468., [Results] We characterized an oncogenic mutation of SPN found in human tumor samples, SPN-A566V, that affects both the SPN-PP1 interaction and its phosphatase activity. The SPN-A566V mutation does not affect the interaction of the PP1-SPN holoenzyme with pocket proteins pRB, p107 and p130, but it affects its ability to dephosphorylate them during G0/G1 and G1, indicating that the PP1-SPN holoenzyme regulates cell cycle progression. SPN-A566V also promoted stemness, establishing a connection between the cell cycle and stem cell biology via pocket proteins and PP1-SPN regulation. However, only cells with both SPN-A566V and mutant p53 have increased tumorigenic and stemness properties., [Conclusions] SPN-A566V, or other equivalent mutations, could be late events that promote tumor progression by increasing the CSC pool and, eventually, the malignant behavior of the tumor., This work was supported by grants from the Ministerio de Ciencia, Innovación y Universidades (MCIU) Plan Estatal de I+D+I 2018, a la Agencia Estatal de Investigación (AEI) y al Fondo Europeo de Desarrollo Regional (MCIU/AEI/FEDER, UE): RTI2018-097455-B-I00 and RTI2018-096735-B-I00 grant from AEI-MICIU/FEDER (RED2018-102723-T); from CIBER de Cáncer (CB16/12/00275), co-funded by FEDER from Regional Development European Funds (European Union); from Consejeria de Salud (PI-0397-2017) and Consejeria of Economía, Conocimiento, Empresas y Universidad of the Junta de Andalucia (P18-RT-2501). Special thanks are also due to the Fundacion AECC and Fundacion Eugenio Rodriguez Pascual for supporting this work.
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Differential effects of tofacitinib on macrophage activation contribute to lack of response in ulcerative colitis patients

  • Melón-Ardanaz, Elisa
  • Veny, Marisol
  • Corraliza, Ana M.
  • Gudiño, Victoria
  • Garrido-Trigo, Alba
  • Sanzo-Machuca, Ángela
  • Buendia, Marc
  • Esteller, Miriam
  • Robbins-Moreno, Lisseth
  • Rodrigo, Maite
  • Masamunt, M. Carme
  • Giner, Ángel
  • Gallego, Marta
  • Ordás, Ingrid
  • Fernández-Clotet, Agnès
  • Caballol, Berta
  • Corbí, Angel L.
  • Verstockt, Bram
  • Vermeire, Séverine
  • Panés, Julián
  • Ricart, Elena
  • Salas, Azucena
16 p.-5 fig.-1 tab.-1 graph. abst., Background and Aims: Tofacitinib, a Janus kinase inhibitor, is approved for the treatment of moderate-to-severe ulcerative colitis. Nonetheless, 40-60% of patients will not respond adequately. The mechanisms underlying responses to tofacitinib remain unknown., Methods: We applied single-cell and/or bulk RNA analysis to biopsies (n = 23 and 63, respectively) from ulcerative colitis patients (n = 31) before and after tofacitinib treatment. Response was assessed using endoscopic and clinical criteria. In vitro-derived macrophages and primary intestinal fibroblasts were used to validate our findings., Results: Forty percent of patients responded to tofacitinib. Responders exhibited higher baseline JAK-STAT activity, while non-responders had increased baseline NF-kB pathway activation. Response was associated with significant changes in the abundance and/or activation of immune, epithelial, and stromal cells and the downregulation of S100A9, FCGR3A, MMP12 in resident macrophages. In contrast, non-responders showed a significant increase in the number and activation of macrophages and fibroblasts following tofacitinib treatment, including upregulation of MMP9, IL1B, IL6, CXCL1, CXCL8, and S100A9 compared to baseline. In monocyte-derived macrophages tofacitinib drove the hyperactivation of macrophages in response to lipopolysaccharide, but not TNF or IFNγ. This effect is dependent on the inhibition of IL-10 signaling, which is abundantly induced in response to LPS, but not to TNF or IFNγ. In contrast, cultured fibroblasts, which produced no IL-10 regardless of the stimuli, showed no hyperactivation when pre-treated with tofacitinib., Conclusions: We conclude that resistance to tofacitinib is mediated by the hyperactivation of myeloid cells and we identify IL-10-dependent macrophages as one cellular subset contributing to this resistance., This work was supported by Pfizer and Grant PID2021-123918OB-100 from the Ministerio de Ciencia e Innovación, Gobierno de España. EM-A was funded by fellowship RH042155 (RTI2018 096946-B-I00) from the Ministerio de Ciencia e Innovación, Gobierno de España., Peer reviewed